NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中國的Tocilizumab市場(2021年∼2025年)

Investigation Report on China's Tocilizumab Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1008257
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Tocilizumab市場(2021年∼2025年) Investigation Report on China's Tocilizumab Market 2021-2025
出版日期: 2021年05月28日內容資訊: 英文 50 Pages
簡介

Tocilizumab(銷售名:Actemra),是Roche Pharma (Schweiz) AG 所開發的生物製藥,用於類風濕性關節炎(RA)的治療。 作為全身型幼年特發性關節炎(SJIA)的治療藥2016年首次在中國批準,2019年納入中國醫保。2020年,中國市場,Roche Pharma (Schweiz) AG 成為唯一的Tocilizumab的製藥企業。

由於2020年Tocilizumab適用保險,2020年承認新的適應症,銷售額從2019年的2,007萬人民幣,到2020年達4,172萬人民幣,以107.89%的成長率擴大。還有從2016年到2020年的年複合成長率記錄16.25%。

本報告提供中國的Tocilizumab市場相關調查,產品概要,新型冠狀病毒感染疾病(COVID-19)的影響,中國整體及各地區的銷售趨勢,製藥企業的市場佔有率,銷售額及銷售額數,價格趨勢,市場預測,市場成長要素,市場機會,課題等彙整資料。

目錄

第1章 Tocilizumab概要

  • Tocilizumab的適應症
  • 中國的Tocilizumab的開發
  • 中國的Tocilizumab的政府核准
  • 新型冠狀病毒感染疾病(COVID-19)對銷售的影響

第2章 中國的Tocilizumab的銷售趨勢(2016年∼2020年)

  • Tocilizumab的銷售額
    • 銷售額:全體
    • 銷售額:各地區
  • Tocilizumab的銷售額數
    • 銷售額數:全體
    • 銷售額數:各地區
  • Tocilizumab的銷售趨勢:各劑型
    • 注射劑
    • 其他劑型

第3章 中國的主要Tocilizumab製造企業(2016年∼2020年)

  • 主要企業的市場佔有率
    • 銷售額
    • 銷售額數
  • Roche Pharma(Schweiz)AG
    • 企業簡介
    • Actemra(ACTEMRA)的中國國內的銷售額

第4章 中國的Tocilizumab的價格(2020年∼2021年)

  • Roche Pharma (Schweiz) AG (Actemra/ACTEMRA)
  • 其他

第5章 中國的Tocilizumab市場預測(2021年∼2025年)

  • 市場發展的影響要素
    • 新型冠狀病毒感染疾病(COVID-19)的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2105492

The trade name of Tocilizumab is ACTEMRA, which was developed by Roche Pharma (Schweiz) AG. In 2013, its product was firstly approved in China and its indication is RA. Tocilizumab was approved in China as the first biological agent for the treatment of sJIA in 2016, was included in China's medical insurance in 2019, and was approved in China for the third indication of CRS in 2020. By 2020, Tocilizumab has registered a number of studies in China, and its indications include RA, sJIA, and CRS. By 2020, Roche Pharma (Schweiz) AG is the only manufacturer in the Chinese Tocilizumab market.

CRI's market research shows that the sales of Tocilizumab have had an increasing trend from 2016 to 2020. Since Tocilizumab was approved for the new indication sJIA in 2016, the sales increase in 2017 with 21.30% of the growth rate from 2016 to 2017. With the inclusion of Tocilizumab in China's medical insurance in 2019 and the approval of its new indications in China in 2020, the sales in 2020 increased evidently, from CNY20.07million in 2019 to CNY41.72 million in 2020. The growth rate is about 107.89%. The CAGR of Tocilizumab was 16.25% from 2016 to 2020.

According to CRI's market research, as the Tocilizumab market will expand from 2021 to 2025, its sales will continue to grow. The patent for the original tocilizumab injection has expired but no biosimilar drug has been approved in China. Currently, five pharmaceutical companies are carrying out relevant clinical trials. After Tocilizumab biosimilars are approved in the market, its manufacturers will gradually increase, the market will continue to grow and the price will decline. These situations will lead to an increase in Tocilizumab sales value and sales volume. In addition, Tocilizumab has been approved for 5 indications in other countries and China has approved 3 indications, so the number of approved indications in China has upside potential. It can be predicted that with the increase of indications, its sales will continue to grow with the expansion of the market in the future.

Topics Covered:

  • The impact of COVID-19 on China's Tocilizumab market
  • Sales value of China's Tocilizumab 2016-2020
  • Competitive landscape of China's Tocilizumab market
  • Prices of Tocilizumab in China
  • Prices of Tocilizumab in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Tocilizumab market
  • Prospect of China's Tocilizumab market from 2021 to 2025

Table of Contents

1 Relevant Concept of Tocilizumab

  • 1.1 Indications for Tocilizumab
  • 1.2 Development of Tocilizumab in China
  • 1.3 Governmental Approval of Tocilizumab in China
  • 1.4 The Impact of COVID-19 on Tocilizumab sales in China

2 Sales of Tocilizumab in China, 2016-2020

  • 2.1 Sales Value of Tocilizumab
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Regions
  • 2.2 Sales Volume of Tocilizumab
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Regions
  • 2.3 Sales of Tocilizumab by Dosage Form in China, 2016-2020
    • 2.3.1 Injection
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Tocilizumab Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Tocilizumab Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Roche Pharma (Schweiz) AG
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of ACTEMRA (Roche Pharma (Schweiz) AG's Tocilizumab) in China

4 Prices of Tocilizumab for Different Manufacturers in China, 2020-2021

  • 4.1 Roche Pharma (Schweiz) AG (ACTEMRA)
  • 4.2 Others

5 Prospect of Chinese Tocilizumab Market, 2021-2025

  • 5.1 Influential Factors of Chinese Tocilizumab Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Tocilizumab Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Tocilizumab Injection Registration in China
  • Chart Sales Value of Tocilizumab Injection over the World
  • Chart Sales Value of Tocilizumab Injection in China, 2016-2020
  • Chart Sales Value of Tocilizumab Injection in China by Regions, 2016-2020
  • Chart Sales Volume of Tocilizumab Injection in China, 2016-2020
  • Chart Sales Volume of Tocilizumab Injection in China by Regions, 2016-2020
  • Chart Market Share by Sales Value of Top Tocilizumab Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of ACTEMRA in China, 2016-2020
  • Chart Referential Prices of ACTEMRA in China by regions, 2020-2021
  • Chart Forecast on Sales Value of Tocilizumab in China, 2021-2025
  • Chart Forecast on Sales Volume of Tocilizumab in China, 2021-2025